Table 2.
Discrete choice experiment participant-reported sociodemographic and clinical characteristics (N = 515)
| Characteristics | Total (N = 515) |
|---|---|
| Age in yearsa, mean (SD) [range] | 62.3 (9.99) [40–88] |
| Men, n (%) | 230 (44.66 %) |
| Employment status, n (%) | |
| Employed, full-time, or part-time | 94 (18.25 %) |
| Retired | 220 (42.72 %) |
| Disabled | 154 (29.90 %) |
| Other | 47 (9.13 %) |
| Highest level of education, n (%) | |
| Elementary/primary school | 2 (0.39 %) |
| Secondary/high school | 136 (26.41 %) |
| Some college | 202 (39.22 %) |
| College degree or more | 162 (31.46 %) |
| Other | 13 (2.52 %) |
| Racial backgroundb, n (%) | |
| White | 490 (95.15 %) |
| Black or African American | 10 (1.94 %) |
| Asian | 1 (0.19 %) |
| American Indian or Alaska Native | 14 (2.72 %) |
| Other | 12 (2.33 %) |
| Hispanic or Latino, n (%) | 10 (1.94 %) |
| Marital status, n (%) | |
| Married | 280 (54.37 %) |
| Divorced | 112 (21.75 %) |
| Never married/single | 22 (4.27 %) |
| Widowed | 65 (12.62 %) |
| Other | 36 (6.99 %) |
| Smoking statusc, n (%) | |
| Current smoker | 178 (34.56 %) |
| Former smoker | 337 (65.44 %) |
| Typical amount smokedc, n (%) | |
| 1 pack/day | 185 (35.92 %) |
| 1½ packs/day | 140 (27.18 %) |
| 2 packs/day | 101 (19.61 %) |
| 2½ packs/day | 48 (9.32 %) |
| ≥3 packs/day | 41 (7.96 %) |
| COPD disease duration, n (%) | |
| <1 year | 23 (4.47 %) |
| 1 to <2 years | 54 (10.49 %) |
| 2 to <5 years | 182 (35.34 %) |
| 5–10 years | 161 (31.26 %) |
| >10 years | 94 (18.25 %) |
| Don’t know | 1 (0.19 %) |
| Participant-reported COPD disease severity, n (%) | |
| Mild | 108 (20.97 %) |
| Moderate | 238 (46.21 %) |
| Severe | 121 (23.50 %) |
| Very severe | 39 (7.57 %) |
| Don’t know | 9 (1.75 %) |
| Current maintenance medication for COPDc, n (%) | |
| Fluticasone propionate and salmeterol inhalation powder (ADVAIR®) | 421 (81.75 %) |
| Budesonide/formoterol fumarate dehydrate (SYMBICORT®) | 66 (12.82 %) |
| Both (ADVAIR and SYMBICORT) | 28 (5.44 %) |
| Rescue medicines for COPDd, n (%) | |
| Albuterol (e.g., VENTOLIN®, PROVENTIL®) | 334 (64.85 %) |
| Levalbuterol (e.g., XOPENEX®) | 30 (5.83 %) |
| Other | 64 (12.43 %) |
| Do not use rescue (quick-relief) medicine | 100 (19.42 %) |
COPD chronic obstructive pulmonary disease, SD standard deviation
aDate of birth was asked in participant eligibility screening. Age was computed using participated-reported date of birth
bParticipants may report more than one category; racial background may not be mutually exclusive
cQuestions about smoking history and current maintenance medicine were asked in eligibility screening
dParticipants may report more than one category; rescue medications may not be mutually exclusive